Atai Life Sciences N.V.
Index- P/E- EPS (ttm)-1.28 Insider Own9.51% Shs Outstand153.97M Perf Week-0.59%
Market Cap537.01M Forward P/E- EPS next Y-1.05 Insider Trans4.22% Shs Float146.43M Perf Month-19.71%
Income-193.50M PEG- EPS next Q-0.23 Inst Own32.30% Short Float4.43% Perf Quarter-20.84%
Sales0.70M P/S767.16 EPS this Y-9.00% Inst Trans13.72% Short Ratio8.30 Perf Half Y-33.27%
Book/sh2.02 P/B1.67 EPS next Y-11.80% ROA-47.50% Target Price23.96 Perf Year-74.94%
Cash/sh1.97 P/C1.72 EPS next 5Y- ROE-52.00% 52W Range2.95 - 17.81 Perf YTD-55.70%
Dividend- P/FCF- EPS past 5Y- ROI-35.00% 52W High-81.02% Beta-
Dividend %- Quick Ratio14.70 Sales past 5Y- Gross Margin- 52W Low14.58% ATR0.26
Employees81 Current Ratio14.70 Sales Q/Q- Oper. Margin- RSI (14)39.35 Volatility7.37% 6.62%
OptionableYes Debt/Eq0.00 EPS Q/Q35.10% Profit Margin- Rel Volume0.82 Prev Close3.46
ShortableYes LT Debt/Eq0.00 EarningsAug 15 BMO Payout- Avg Volume780.64K Price3.38
Recom1.80 SMA20-8.44% SMA50-17.22% SMA200-28.50% Volume643,944 Change-2.31%
Nov-30-21Initiated Maxim Group Buy $25
Nov-11-21Initiated ROTH Capital Buy $32
Oct-18-21Initiated H.C. Wainwright Buy $40
Sep-01-21Initiated Jefferies Buy $27
Jul-13-21Initiated RBC Capital Mkts Sector Perform $19
Jul-13-21Initiated Credit Suisse Outperform $25
Jul-13-21Initiated Cowen Outperform
Jul-13-21Initiated Citigroup Buy $26
Jul-13-21Initiated Cantor Fitzgerald Buy $45
Jul-13-21Initiated Canaccord Genuity Buy $28
Jul-13-21Initiated Berenberg Buy $35
Jul-08-21Initiated Aegis Capital Buy $26
Oct-05-22 07:00AM
Oct-04-22 07:00AM
Sep-27-22 08:00AM
Sep-06-22 06:30PM
Aug-15-22 07:35AM
06:55AM Loading…
Aug-01-22 06:59AM
Jul-22-22 06:40AM
Jul-12-22 12:10PM
Jun-30-22 06:59AM
Jun-17-22 06:59AM
Jun-16-22 05:59AM
Jun-15-22 10:21AM
May-16-22 06:55AM
May-06-22 11:20AM
03:19PM Loading…
May-05-22 03:19PM
May-04-22 04:00AM
Apr-19-22 03:22PM
Apr-13-22 10:00AM
Mar-30-22 06:59AM
Mar-23-22 06:59AM
Mar-21-22 01:08PM
Feb-16-22 06:59AM
Feb-15-22 06:59AM
Jan-12-22 06:59AM
Jan-10-22 01:03PM
Dec-29-21 08:40AM
Dec-23-21 06:48AM
Dec-22-21 01:43PM
07:30AM Loading…
Dec-17-21 07:30AM
Dec-16-21 06:59AM
Dec-15-21 04:19PM
Dec-14-21 07:30AM
Dec-13-21 06:59AM
Dec-09-21 10:30AM
Dec-06-21 07:01AM
Nov-29-21 07:00AM
Nov-15-21 06:59AM
Nov-08-21 08:30AM
Nov-05-21 04:30PM
Nov-02-21 04:43PM
Nov-01-21 05:20PM
Oct-27-21 09:36AM
Oct-26-21 06:50AM
Oct-19-21 07:00AM
Oct-18-21 01:37PM
Oct-11-21 08:00AM
Sep-27-21 09:19AM
Sep-21-21 08:00AM
Sep-20-21 12:51PM
Sep-15-21 08:10AM
Sep-14-21 08:00AM
Sep-09-21 04:30PM
Sep-03-21 06:00PM
Sep-02-21 12:21PM
Aug-31-21 10:33AM
Aug-16-21 08:42AM
Aug-14-21 09:34AM
Aug-12-21 01:20PM
Aug-09-21 06:00PM
Aug-06-21 06:10PM
Aug-04-21 12:07PM
Aug-03-21 02:23PM
Aug-02-21 10:08AM
Jul-29-21 04:26PM
Jul-28-21 05:32PM
Jul-19-21 07:24AM
Jul-16-21 03:56PM
Jul-15-21 02:46PM
Jul-14-21 12:57PM
Jul-09-21 08:24AM
Jul-07-21 07:47PM
Jul-06-21 04:47PM
Jul-03-21 06:40AM
Jun-29-21 02:42PM
Jun-21-21 10:21AM
Jun-18-21 05:28PM
Jun-17-21 11:21PM
Aug-12-20 04:05PM
Aug-05-20 08:00AM
Jul-09-20 08:00AM
Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder; RLS-01, a formulation of Salvinorin A for TRD; KUR-101, an oral formulation of deuterated mitragynine to treat OUD; and DMX-1001, an oral formulation of noribogaine for the treatment of OUD. The company was formerly known as Adripa Holding B.V. Atai Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Apeiron Investment Group Ltd.10% OwnerApr 29Buy4.4721,90097,8011,799,302May 02 04:15 PM
Apeiron Investment Group Ltd.10% OwnerApr 28Buy4.4634,700154,6891,777,402May 02 04:15 PM
Apeiron Investment Group Ltd.10% OwnerApr 27Buy4.6419,80391,9391,742,702Apr 28 04:26 PM
Apeiron Investment Group Ltd.10% OwnerApr 26Buy4.6946,207216,6281,722,899Apr 28 04:26 PM
Apeiron Investment Group Ltd.10% OwnerApr 25Buy4.788,96142,8431,676,692Apr 26 04:15 PM
Apeiron Investment Group Ltd.10% OwnerApr 22Buy4.8352,820254,9621,667,731Apr 26 04:15 PM
Apeiron Investment Group Ltd.10% OwnerApr 21Buy4.9568,688340,0401,614,911May 03 04:16 PM
Apeiron Investment Group Ltd.10% OwnerApr 20Buy5.0967,703344,5131,546,223May 03 04:16 PM
Apeiron Investment Group Ltd.10% OwnerApr 19Buy5.1265,315334,7391,478,520Apr 20 04:30 PM
Apeiron Investment Group Ltd.10% OwnerApr 18Buy5.1154,322277,6561,413,205Apr 20 04:30 PM
Apeiron Investment Group Ltd.10% OwnerApr 14Buy5.194,96725,7791,358,883Apr 18 04:15 PM
Apeiron Investment Group Ltd.10% OwnerApr 12Buy4.8855,197269,5601,353,916Apr 14 04:15 PM
Apeiron Investment Group Ltd.10% OwnerApr 11Buy4.8353,926260,5541,298,719Apr 12 04:30 PM
Apeiron Investment Group Ltd.10% OwnerApr 08Buy4.8157,689277,6401,244,793Apr 12 04:30 PM